Chemosensory Receptor Ligand-Based Therapies
AssigneeElcelyx Therapeutics, Inc.
InventorsAlain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
Claims59
A composition comprising a chemosensory receptor ligand selected from the following structures:
- wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.
A composition comprising a chemosensory receptor ligand selected from a compound of structural Formula I,
- wherein
- Aa is an amino acid residue bonded to the adjacent carbonyl group via the N-alpha nitrogen and is selected from the group consisting of,
- alanine (Ala), isoleucine (Ile), leucine (Leu), methionine (Met), tert-leucine (t-Leu), and valine (Val);
- and
- n is an integer between 8 and 22;
- and
- wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.
A composition comprising a chemosensory receptor ligand selected from a di- or tripeptide compound of structural Formula II,
- wherein
- Aa1 is an amino acid residue bonded to the adjacent carbonyl group via the N-alpha nitrogen and is selected from the group consisting of,
- aminobutyric acid (Abu), alanine (Ala), aspartic acid (Asp), cysteine (Cys), S-methyl cysteine (Cys(SMe)), S-methyl cysteine sulfoxide (Cys(SMe)(O)), S-allyl cysteine (Cys(S-allyl), S-nitroso cysteine (Cys(SNO)), glutamic acid (Glu), γ-glutamic acid (γ-Glu), glycine (Gly), isoleucine (Ile), leucine (Leu), methionine (Met), methionine-5-sulfoxide (Met(O)), ornithine (Orn), serine (Ser), taurine (Tau), threonine (Thr), tert-leucine (t-Leu), valine (Val), valinamide (Val-NH2), and valinol (Val-ol);
- and
- Aa2 is either absent or is an amino acid residue bonded to the adjacent carbonyl group via the N-alpha nitrogen selected from a group consisting of,
- arginine (Arg), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), glutamic acid (Glu), glutamine (Gln), glycine (Gly), lysine (Lys), methionine (Met), ornithine (Orn), phenylalanine (Phe), proline (Pro), serine (Ser), and valine (Val);
- and
- wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.
A composition comprising a chemosensory receptor ligand that is a dipeptide compound selected from the following:
- Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp and Asp-Cys;
- and
- wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.
A composition comprising a chemosensory receptor ligand having the formula γ-Glu-X-Gly, wherein X is selected from:
- Ala, Leu, Ile, Thr, Met, Asn, Gln, Pro, hydroxproline, Asp, Glu, Lys, Arg, His, Phe, Tyr, Trp, homoserine, citrulline, Orn, norvaline, norleucine, and Tau;
- and wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.
A composition comprising a chemosensory receptor ligand comprising poly-γ-glutamic acid having a weight-average molecular weight of equal to or greater than 3×103;
- and wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.
A composition comprising a chemosensory receptor ligand selected from a compound of structural Formula III,
- wherein
- R1 and R2 are each independently selected from:
- C1-C10 substituted or unsubstituted straight chain or branched chain alkyl, substituted or unsubstituted C4-C10 alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted alkyl heteroaryl;
- and
- wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.
(canceled)
A composition comprising a chemosensory receptor ligand selected from the following structures:
- wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.
A composition comprising a chemosensory receptor ligand selected from a compound of structural Formula IV,
- wherein
- R1 and R3 are each independently selected from:
- H, OH, F, Cl, Br, I, C1-C6 straight chain or branched chain alkyl, O—(C1-C6 straight chain or branched chain alkyl), O—(C3-C7 cycloalkyl), O—(C4-C8 alkylcycloalkyl) and SO3H;
- R2 is independently selected from:
- H, SO3H, CO2H, PO3H2, PO2(OCH3)H and NO2;
- R4 is independently selected from:
- H, OH, F, Cl, Br, I and NO2,
- R5 is independently selected from:
- H, F, Cl, Br, I and C1-C6 straight chain or branched chain alkyl;
- and
- with the proviso that at least two of R1, R2, R3, R4 and R5 are H;
- R6 is selected from:
- H, OH and C1-C6 straight chain or branched chain alkyl;
- and
- X is selected from:
- CH2 and O;
- and
- wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.
A composition comprising a chemosensory receptor ligand selected from the following structures:
- wherein n is an integer between 0 and 10;
- and
- wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.
(canceled)
(canceled)
(canceled)
A composition according to claim 31, wherein said sweet receptor ligand is selected from the group consisting of sucralose, aspartame, Stevioside, Rebaudioside A, Rebaudioside B, Rebaudioside C, Rebaudioside D, Rebaudioside E, Rebaudioside F, Neotame, acesulfame-K, saccharin, and polymorphs thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.